In analyst calls reported on November 20, 2026, firms took opposing views on Anthropic and issued ratings changes across technology, health care and other sectors. These are analysts’ assessments and forecasts, not confirmed future results.
Technology and consumer companies
- Anthropic: Seaport initiated coverage at neutral, citing a sharp slowdown in third-quarter revenue growth and uncertainty about the fourth quarter. William Blair initiated coverage at outperform, arguing that Anthropic is at the forefront of AI development while acknowledging substantial uncertainty about the market’s future.
- STMicroelectronics: Roth initiated coverage at buy with a $58 price target, describing the company as one of the few large-scale Western integrated device manufacturers with a broad product line.
- Apple: UBS reiterated neutral. Its availability data across more than 30 geographies showed average wait times for Apple’s Duo falling by about 21 days week over week to roughly 53 days.
- Netflix: Bernstein reiterated outperform. It said double-digit revenue growth in 2027 was possible, though pricing would likely have to contribute substantially.
- Tesla: HSBC upgraded the stock to hold from reduce. The firm said the strategic logic of a Tesla–SpaceX merger under review was not immediately apparent; it suggested control might be a motive. That is HSBC’s assessment, not confirmation that a merger will occur.
- PDD Holdings: Macquarie upgraded the stock to outperform from market perform and raised its price target by 8%. It cited signs that Temu was approaching profitability despite macroeconomic pressure on the core e-commerce business.
- SpaceX: Morgan Stanley reiterated overweight, arguing that the market undervalues Starlink’s potential to provide connectivity to robots.
- Amazon: Oppenheimer reiterated outperform and raised its price target to $310 from $285. In its valuation, the firm estimated Amazon’s Anthropic holdings at approximately $339 billion, assuming full conversion of the securities it holds and a price of $97 for each of roughly 3.5 billion shares. The estimate is Oppenheimer’s, not an established market value.
Health care, energy and other calls
- Evolent: Truist upgraded the stock to buy from hold, keeping its $6 price target. It said visibility into 2027 had improved and EBITDA above $150 million looked increasingly achievable.
- UnitedHealth and Humana: TD Cowen upgraded both from hold to buy. It projected a path to mid-to-high-teens earnings-per-share growth for UnitedHealth through 2028. For Humana, it cited a potential step-up in 2027 earnings growth and earnings per share above $40 in 2028.
- Supernus: Wells Fargo initiated coverage at overweight, citing commercial growth potential.
- Village Farms International: Canaccord initiated coverage at buy with a 12-month price target of US$5.50, arguing that the market underappreciated the cannabis company’s export business.
- MSG Rangers: JPMorgan initiated coverage at overweight following a spinout from MSG Sports, pointing to ownership of the New York Rangers.
- Everforth: BMO upgraded the stock to outperform from market perform, citing its valuation after a sell-off.
- Oklo: Guggenheim upgraded the stock to buy from neutral with a $38 price target, citing progress toward milestones in its power, isotopes and fuel businesses.
- Berkshire Hathaway: Argus downgraded the stock to hold from buy. It said the shares were fully valued at about 25 times its forecast for 2027 operating earnings per share.


